Pluri Biotech

26/03/2026

Big news from Pluri Inc.! 🚀
Our Chairman of the Board, Alejandro Weinstein, is doubling down on his commitment to Pluri’s future with an additional $2.5 million investment-at a 30% premium to the market price!
This investment is a powerful signal of confidence in our team, our technology, and our mission to solve global challenges through cell-based solutions. As CEO Yaky Yanay noted, we are focused on unlocking the immense value within our platform to benefit our shareholders and the world.
Stay tuned as we continue to push the boundaries of biotechnology!

Read more: https://eur05.safelinks.protection.outlook.com/?url=https%3A%2F%2Fpluri-biotech.com%2Freleases%2Fpluri-secures-additional-investment-from-chairman-alejandro-weinstein-at-30-premium-to-market-in-a-private-placement%2F&data=05%7C02%7Cnofargl%40Pluri-biotech.com%7C429d557d505843696f4d08de8b464c6e%7Cdddc407fde4d434984cbc328e55f7e8a%7C0%7C0%7C639101331221350281%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=jswpOAeIoo5wlcxJMJTb1sFLgZWRDtvmjw%2F8muCIpCo%3D&reserved=0
$PLUR

Haifa, Israel – March 26, 2026 – Pluri Inc. (“Pluri” or the “Company”) (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today announced that an entity beneficially owned by Alejandro Weinstein, Chairman of th...

23/02/2026

We’re pleased to share recent media coverage highlighting the collaboration between Kokomodo, a Pluri subsidiary, and Cargill, supported by EIT Food, to evaluate cultivated cacao for future commercial food applications.

The article explores how cellular agriculture may help address climate, supply, and price volatility challenges in the global cocoa industry, while maintaining the authentic qualities of cacao.

Functional validation results are expected in the coming months, with potential commercialization pathways beginning as early as 2027, subject to regulatory review.

Read the full article below.

Kokomodo has joined forces with Cargill in a project supported by European food innovation initiative, EIT Food, to evaluate cell-based cacao ingredients for commercial food applications. It comes in the wake of the cocoa crisis, which saw prices skyrocket and heavily impact confectionery and chocol...

18/02/2026

Below is a feature published on Channel 24 highlighting Pluri’s vision for healthy aging and longevity.

As global populations age, physical decline and chronic health challenges are becoming increasingly significant. At Pluri, we are developing scalable cell-based solutions designed to support regeneration, rehabilitation, and natural healing processes — helping improve wellbeing and quality of life over time.

Articles: https://www.i24news.tv/enFacebook: https://www.facebook.com/i24newsEN/Twitter: https://twitter.com/i24NEWS_ENInstagram: https://www.instagram.com/i...

10/02/2026

🚀 Pluri Inc CEO Yaky Yanay spoke with Proactive about Pluri’s proprietary cell expansion platform, developed over 20+ years and supported by ~250 patents.

Pluri’s platform is designed for scalable, reproducible, and cost-efficient cell production, enabling the transition of advanced cell-based products from development to commercial-scale manufacturing across therapeutics and FoodTech.

Pluri has also completed Phase I of its collaboration with Resbiomed Technologies OOD through PluriCDMO, with the program now advancing to the next phase.

Pluri Inc CEO Yaky Yanay joined Steve Darling from Proactive to provide deeper insight into the company’s proprietary cell expansion technology and its...

08/02/2026

In a recent article, Alejandro Weinstein, Chairman of Pluri, discusses the often underappreciated value behind Pluri’s platform: its cell expansion technology.

Pluri’s technology is designed to enable the expansion of cells derived from virtually any living cell source, with the ability to scale production in a consistent and controlled manner. This capability positions the platform as a foundational enabler across multiple industries—from cell therapy and regenerative medicine to cultivated food and agriculture.

As global demand grows for scalable, reliable, and sustainable cell-based solutions, platform technologies that can operate across applications and at industrial scale represent a significant long-term opportunity.

https://pluri-biotech.com/ Biotechnology breakthroughs don’t create value unless they reach the market.From the floor of the New York Stock Exchange, Jane Ki...

04/02/2026

Alejandro Weinstein, Chairman of Pluri, explains how Pluri’s technology enables large-scale expansion of a wide range of cell-based products grown in controlled laboratory environments.

By supporting scalable cell cultivation for cultivated meat and plant-based solutions, Pluri’s platform has the potential to reduce pressure on natural resources and support climate-resilient food and agriculture systems.

Alejandro Weinstein, Chairman of Pluri, shares insights on the future of biotechnology and cell-based therapies. Weinstein explores how advanced biotech enables large-scale growth of animal and plant cells, creating sustainable alternatives to traditional agriculture and paving the way for innovatio...

28/01/2026

Pluri is entering a new chapter. Under the leadership of Chairman Alejandro Weinstein, the company is transitioning from a research-driven biotech into a commercially focused platform company, unlocking the full value of its patented 3D cell-expansion technology.
By sharpening its focus on high-impact verticals in human health, longevity, and sustainable food production—including cultivated cacao and cell-based coffee—Pluri is building scalable businesses designed to address some of the world’s most urgent challenges while creating meaningful long-term value.

Pluri Inc. is evolving into a commercial-driven biotech leader under Chairman Alejandro Weinstein, unlocking its 3D cell-expansion platform across longevity and AgTech.

27/01/2026

Pluri has successfully completed the first phase of its program with Resbiomed, demonstrating its ability to translate complex, placenta-derived biomaterials into scalable, reproducible manufacturing processes.
Executed through PluriCDMO™, the program highlights Pluri’s strengths in advanced bioprocessing, process definition, and manufacturing readiness for collagen-rich and ECM-based products.
This milestone reinforces PluriCDMO’s position as a trusted CDMO partner for companies developing next-generation biologics and advanced biomaterials.

https://www.manilatimes.net/2026/01/22/tmt-newswire/globenewswire/pluri-successfully-completes-first-phase-of-resbiomed-program-for-placenta-derived-collagen-rich-biomaterials/2263691

HAIFA, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Pluri, Inc. ('Pluri”, the 'Company”, 'we” or 'us”) (Nasdaq, TASE: PLUR), a biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced the completion of the fi...

20/01/2026

Yaky Yanay, CEO of Pluri Inc., in an interview with Jane King – now live on YouTube.

In the conversation, Yaky shares Pluri’s vision, how a cell-based platform built over two decades is now enabling multiple products across pharma, food, agriculture, and aesthetics, and how science-driven innovation can translate into real-world impact.

🎥 Worth a watch.

https://pluri-biotech.com/ From the New York Stock Exchange, Jane King sits down with Yaky Yanay, CEO & President of Pluri (NASDAQCM, TASE: PLUR), to explore...

18/01/2026

גאים לשתף כתבה שפורסמה ב־וואלה כסף, ובה הוזכרה Pluri כחלק מהשיח על שוויון הזדמנויות והעסקה הוגנת במשק.

פלורי היא חברת טכנולוגיה לפיתוח וגידול תאים בקנה מידה תעשייתי, הן מן החי והן מן הצומח, עם יישומים ברפואה רגנרטיבית, פודטק, אגרוטק ותעשיות מתקדמות נוספות.
הטכנולוגיה שלנו מאפשרת ייצור עקבי, יעיל ובר־קיימא של תאים – לצד תרבות ארגונית שמקדמת גיוון, שוויון והזדמנויות אמיתיות.

הכתבה מדגישה נקודה חשובה:
שוויון מגדרי ותרבות של העסקה הוגנת אינם רק ערך חברתי – אלא בסיס לחדשנות, צמיחה ומצוינות טכנולוגית.

📌 לקריאת הכתבה המלאה:

פערי שכר מגדריים הם לא גזירת גורל – הם החלטה ניהולית. בזמן שהמשק מגמגם, לפחות 17 חברות בישראל כבר מתנהלות אחרת

28/12/2025

We are proud to share the expansion of Pluri’s collaboration with Remedy Cell, following the successful implementation of Remedy Cell’s proprietary manufacturing process at our GMP facility.
Together with Remedy Cell’s team, PluriCDMO™ completed GMP training and qualification, executed engineering runs to validate robustness and scalability, and manufactured multiple clinical-grade batches for Remedy Cell’s upcoming Phase 1b clinical trial.
This milestone highlights PluriCDMO™’s ability to support complex cell-derived and cell-free processes with consistent, scalable, and regulatory-compliant manufacturing solutions — and reflects our commitment to enabling innovative therapies on their path to the clinic.
We look forward to continuing this productive partnership as Remedy Cell advances its clinical and pre-commercial programs.